[50] showed that GALNT14 may be a predictive biomarker for dulanermin-based therapy in NSCLC because they found that sensitivity to dulanermin (a protein that induces apoptosis in tumor cells) was strongly correlated with the overexpression of GALNT14. They also found a functional link between death receptor O-glycosylation and apoptotic signaling showing that the both pharmacologic inhibition of glycosylation and enzyme knockdown through small interfering RNAs targeting GALNT14 reduced dulanermin-induced apoptosis [45]. The gene discussed is GALNT14; the disease is neoplasm.